Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20740435 | 1.00 | NPSR1 (0.48) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL1606853 | 0.98 | NPSR1 (0.50) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL691739 | 0.93 | — | — | |
| SCHEMBL9008361 | 0.87 | — | — | |
| SCHEMBL758201 | 0.78 | NPSR1 (0.50) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL7420059 | 0.78 | NPSR1 (0.50) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL24780851 | 0.77 | CYP3A4 (0.41) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL20335470 | 0.77 | NPSR1 (0.36) | NPSR1CYP4F2CYP4A11LMNA | |
| SCHEMBL374351 | 0.75 | NPSR1 (0.52) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL594374 | 0.75 | NPSR1 (0.52) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119735532-A | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119431227-A | Azacarbene catalysis is coupled by decarboxylation of (a) | 中国海洋大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-112824380-B | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-117720517-A | AR inhibitor, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-114573485-B | Method for synthesizing alkynyl alkyl sulfide | 华南理工大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-114315508-B | Technological method for synthesizing cyclopropyl bromide | 大连双硼医药化工有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-114573485-A | Method for synthesizing alkynyl alkyl thioether | 华南理工大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-112824380-A | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2021-05-21 | — | — | CN | disclosed |
| EP-3444254-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20050020652-A1 | Peroxisome proliferator activated receptor agonists | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| WO-2004092145-A1 | ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS | PFIZER INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
| EP-1453811-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1372655-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003048130-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002069901-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-09-12 | — | — | WO | disclosed |
| US-4816452-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1989-03-28 | — | — | US | disclosed |
| EP-0210815-A2 | 6-Beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use | BEECHAM GROUP PLC (GB) | 1987-02-04 | — | — | EP | disclosed |
| US-4082913-A | ANTI-ATHEROSCLEROSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | NPSR1 1639/4885MAPT 3191/4885CYP4F2 3589/4885 |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | CDK4, CDK6, CCNI | NPSR1 4510/4885MAPT 2593/4885CYP4F2 1497/4885 |
| US-20050020652-A1 | Peroxisome proliferator activated receptor agonists | PPARA, PPARD, PPARG | NPSR1 712/4885MAPT 4870/4885CYP4F2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.